NCT00315731View on ClinicalTrials.gov

A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 31, 2003

Primary Completion Date

December 4, 2006

Study Completion Date

June 30, 2013

Conditions
Lymphoma, Follicular
Interventions
BIOLOGICAL

Follicular Lymphoma

For subjects with previously untreated or relapsed follicular or transformed follicular non-Hodgkin's

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY